HOME >> MEDICINE >> NEWS
Starting dose of Lexapro as effective as optimally dosed Zoloft in the treatment of depression

NEW YORK, December 10 Forest Laboratories, Inc. (NYSE: FRX) announced today the results of a clinical study, which showed that LexaproTM (escitalopram oxalate) is as effective and well tolerated as Zoloft (sertraline hydrochloride). The purpose of the study was to evaluate whether the starting dose of Lexapro, 10 mg per day, could provide comparable efficacy to the full dosing range of Zoloft, 50 200 mg per day. Study results showed that patients receiving a dose of 10 mg per day of Lexapro experienced similar efficacy compared to patients receiving a median dose of Zoloft of 150 mg per day. At week four, 46 percent of Zoloft-treated patients received 150 mg per day or higher, and at week eight, 65 percent received 150 mg per day or higher. To achieve a dose of 150 mg per day or higher, patients treated with Zoloft required at least two dose titrations. Both Lexapro and Zoloft belong to a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). The study was presented in Puerto Rico at an annual meeting of neuropsychopharmacologists.

"In this study, most patients experienced relief from depressive symptoms. Patients treated with Lexapro received 10 mg throughout the study period, while patients treated with Zoloft received dosages based on depressive symptoms and the development of side effects," said George Alexopoulos, M.D., Professor of Psychiatry at Weill Medical College of Cornell University. "Lexapro is an effective treatment for depression with simple dosing that may improve patient adherence."

Each year, nearly 19 million adult Americans suffer from mild, moderate, or severe depression. One in 4 women and 1 in 10 men can expect to be diagnosed with depression during their lifetime. Depression costs the United States an estimated $44 billion each year. The World Health Organization predicts depression will become the leading cause of disability by the year 2020.

Study Conclusions<
'"/>

Contact: Charles E. Triano
212-224-6714
Forest Laboratories
10-Dec-2003


Page: 1 2 3

Related medicine news :

1. Starting beta-blocker before discharge in patients hospitalized for heart failure increases usage
2. Lexapro receives FDA approval for the treatment of generalized anxiety disorder
3. Strategy effective against drug resistant tuberculosis
4. Study shows patch therapy may be as effective as oral medications
5. Chronic pain treatments more effective when taken together, new study shows
6. Geodon effective in psychiatric emergencies; Sharply reduces time in restraints
7. Costs of antidepressants could have funded effective alternatives
8. New ways to design safer & more effective topical (transdermal) drug delivery announced in the PNAS
9. Government wasting your taxpayer money on ineffective drug cure
10. Neurobehavioral function during coma, stroke rehabilitation effective for elderly
11. European folic acid policies are not effective enough

Post Your Comments:
(Date:3/28/2015)... Rocket Pure , a manufacturer of natural body ... new natural sunscreen. They are offering the sunscreen in ... come with a bonus lip balm sunscreen. , The new ... Click to see the natural sunscreen on Amazon . ... made with non-nano zinc oxide and provides broad-based protection against ...
(Date:3/28/2015)... With more than 4,500 scientists, clinicians and ... and musculoskeletal diseases gathered here for the World ... time in the 17-year history of the field’s ... is an emerging non-pharmaceutical protocol for enhancing bone ... Wolff’s law, osteogenic loading at multiples of body ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 An article ... problem which could prove critical to organizations that deal ... a critical aspect of data security, is worsening . ... data security report, every major category out of the ... penetration testing. “With all the craziness that has gone ...
(Date:3/28/2015)... 28, 2015 Delaying rotator cuff surgery ... according to research presented today at the American Orthopaedic ... , “Our study compared results for 170 patients who ... additional glenohumeral joint capsule release procedure to relieve stiffness ... PhD, lead author from St. George Hospital in Sydney, ...
(Date:3/28/2015)... Omaha, NE (PRWEB) March 28, 2015 ... leader in healthcare staffing, including physical therapy jobs, ... exhibitor at the Ohio Physical Therapy Association Annual ... the Renaissance Columbus Downtown Hotel in Columbus, OH. ... programming, networking opportunities, and exhibits with products and ...
Breaking Medicine News(10 mins):Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 2Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2
(Date:3/27/2015)... , March 27, 2015   Hospira, Inc. ... in biosimilars and the world,s leading provider of ... that support an evaluation of biosimilarity of its ... and Drug Administration (FDA) conditionally approved name of ... (epoetin alfa). These study data were presented at ...
(Date:3/27/2015)... NEW YORK , March 27, 2015 /PRNewswire/ ... specialty pharmaceutical and medical device company focused on ... primary and metastatic liver cancers, announces the reporting ... the Company,s Melphalan Hydrochloride for Injection with the ... therapies in a poster presentation at the Society of ...
(Date:3/26/2015)... March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... a focus on Omega-3 therapies for cardiovascular disease and ... issued 763,752 common shares of the Corporation (the "Common ... the period of December 5 th , 2014 to ... Notes that is due on or before April 1, ...
Breaking Medicine Technology:Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2
Cached News: